NCT04999202: A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults

NCT04999202
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for dose escalation phase
Exclusions: Patients who have not progressed on treatment with an anti-PD1/L1 monoclonal antibody (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with known active central nervous system (CNS metastases and/or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04999202

Comments are closed.

Up ↑